Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Dow
McKesson
Express Scripts
Moodys

Last Updated: January 24, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Misonidazole

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Misonidazole?

Misonidazole is an investigational drug.

There have been 13 clinical trials for Misonidazole. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2012.

The most common disease conditions in clinical trials are Glioblastoma, Lung Neoplasms, and Carcinoma, Squamous Cell. The leading clinical trial sponsors are National Cancer Institute (NCI), Proacta, Incorporated, and University of Arkansas.

There are seven hundred and eighty-one US patents protecting this investigational drug and six international patents.

Recent Clinical Trials for Misonidazole
TitleSponsorPhase
Feasibility of FMISO in Brain TumorsNational Cancer Institute (NCI)Phase 2
Feasibility of FMISO in Brain TumorsOHSU Knight Cancer InstitutePhase 2
Pilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjects With Recurrent Glioblastoma Before and After Bevacizumab TreatmentAbramson Cancer Center of the University of PennsylvaniaPhase 1

See all Misonidazole clinical trials

Clinical Trial Summary for Misonidazole

Top disease conditions for Misonidazole
Top clinical trial sponsors for Misonidazole

See all Misonidazole clinical trials

US Patents for Misonidazole

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Misonidazole   Start Trial 1H-pyrrolo[2,3-B] pyridine derivatives and their use as kinase inhibitors Vernalis (R&D) Limited (Winnersh, GB)   Start Trial
Misonidazole   Start Trial Anti-transglutaminase 2 antibodies LifeArc (London, GB)   Start Trial
Misonidazole   Start Trial Pharmaceutical compounds Cascadian Therapeutics, Inc. (Seattle, WA)   Start Trial
Misonidazole   Start Trial Small molecule HSP70 inhibitors The Trustees of the University of Pennsylvania (Philadelphia, PA) The Wistar Institute of Anatomy and Biology (Philadelphia, PA)   Start Trial
Misonidazole   Start Trial Macrocylic pyrimidine derivatives Janssen Pharmaceutica NV (Beerse, BE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Misonidazole

Drugname Country Document Number Estimated Expiration Related US Patent
Misonidazole Australia 2013213954 2032-01-30   Start Trial
Misonidazole Brazil 112014018795 2032-01-30   Start Trial
Misonidazole Canada 2862940 2032-01-30   Start Trial
Misonidazole China 104203948 2032-01-30   Start Trial
Misonidazole China 106866658 2032-01-30   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Merck
Express Scripts
Mallinckrodt
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.